Therapy Areas: Cardiovascular
Precigen Commences Phase 1 Clinical Study of Triple-effector Plasmid in LVAD Patients
23 May 2018 - - Germantown, Maryland-based biopharmaceutical company Precigen, Inc., a wholly-owned subsidiary of synthetic biology company Intrexon Corp. (NYSE: XON), has treated the first patient in a Phase 1 first-in-human clinical trial of its investigational therapy, INXN-4001, the company said.
INXN-4001 is a non-viral, multigene plasmid designed to express three different human proteins. A unique triple-effector plasmid, INXN-4001 addresses multiple malfunctions of cardiomyocytes in patients with heart failure.
INXN-4001 is being studied clinically to assess its safety and feasibility of minimally invasive retrograde coronary sinus infusion (RCSI) in left ventricular assist device (LVAD) patients.
This first INXN-4001 clinical study is designed to evaluate the safety of INXN-4001 in LVAD patients as assessed by the incidence rate of all adverse events occurring up to six months post-treatment.
The study will also examine the ability of LVAD patients to wean from the LVAD device, their quality of life, and their overall daily activity.
INXN-4001 represents the leading program in Precigen's majority-owned subsidiary Xogenex, LLC, a company focused on the development of multi-genic biological therapies for cardiovascular disease.
Precigen is advancing the next generation of gene and cellular therapies using precision technology to target the most urgent and intractable diseases in oncology, autoimmune disorders, and emerging specialty therapy areas.
The company operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-confidence and commercialisation.
Login
Username:

Password: